Table 3.

NAFLD among individuals with metabolic abnormalities

	Prevalence of NAFLD % (95% CI)	Percentage of NAFLD with elevated liver enzymes	Hepatic steatosis compared to controls
			aOR* (95% CI)	p value
Metabolic syndrome	43.2 (39.4 – 46.9)	19.9% (1.9)	11.5 (8.9 – 14.7)	<0.001
Three abnormalities	37.3 (33.7 – 41.0)	18.1% (2.4)	9.7 (7.6 – 12.5)	<0.001
Four abnormalities	48.5 (43.9 – 53.1)	21.6% (3.8)	16.9 (12.0 – 23.8)	<0.001
Five abnormalities	67.3 (56.7 – 77.8)	22.8% (4.5)	37.6 (25.0 – 56.3)	<0.001
Increased WC†	31.2 (28.6 – 33.9)	17.1% (1.6)	2.9 (2.2 – 3.8)	<0.001
IFG/Diabetes†	41.2 (36.6 – 45.9)	20.3% (2.8)	2.0 (1.2 – 3.4)	0.007
High Triglyceride level†	34.7 (31.8 – 37.6)	19.0% (2.1)	2.2 (1.5 – 3.0)	<0.001
Low HDL level†	27.8 (25.1 – 30.4)	17.6% (2.0)	1.5 (1.2 – 1.9)	<0.001
High BP†	29.2 (26.5 – 31.9)	17.9% (1.9)	1.3 (0.9 – 1.8)	0.060

Abbreviations: NAFLD – nonalcoholic fatty liver disease, WC – waist circumference, IFG – impaired fasting glucose, HDL – high density lipoprotein,

^*aOR – adjusted odds ratio (adjusted for age, sex, race, smoking, alcohol use, and education level), CI – confidence interval, S.E. – standard error of percentage

^†Odds ratio further adjusted for other metabolic abnormalities